Saar I. Gill, MD, PhD, of the University of Pennsylvania, discusses findings from a prospective clinical trial on the high response rate in patients with chronic lymphocytic leukemia who received a combination therapy of CAR T cells plus ibrutinib (Abstract 298).
Francesca M. Gay, MD, of GIMEMA, European Myeloma Network, discusses study findings on the use of carfilzomib in induction combination regimens with autologous transplantation, and consolidation regimens in newly diagnosed multiple myeloma (Abstract 121).
Alexander B. Pine, MD, PhD, of Yale School of Medicine, discusses a survey gathering data on health-care providers’ practices and preferences in using direct oral anticoagulant therapy to treat venous thromboembolism.
Readers of The ASCO Post are invited to participate in this research by completing the survey, entitled: “Perspectives and Practices in Utilization of Direct Oral Anticoagulants in Patients With Cancer-Associated Venous Thromboembolism.” The survey takes approximately 3 to 4 minutes to complete and can be taken on a mobile device or a computer. The survey link is https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_3l0HxrreWZhVtBz.
John P. Leonard, MD, of Weill Cornell Medicine/Cornell University, discusses phase III findings on lenalidomide plus rituximab vs rituximab plus placebo for people with relapsed or refractory indolent non-Hodgkin lymphoma (Abstract 445).
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses a study by the Lunenburg Lymphoma Biomarker Consortium that confirmed previous reports on the negative prognostic impact of an underlying MYC-translocation for both progression-free and overall survival in diffuse large B-cell lymphoma (Abstract 344).
Tait D. Shanafelt, MD, of Stanford University, discusses phase III study findings on ibrutinib-based therapy vs standard fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (Abstract LBA4).
